Sentence examples for license trials from inspiring English sources

But those who license trials in Britain must be more demanding than usual of ReNeuron in establishing that they have powerful evidence from their lab work to make the risk of delving into the unpredictable brain worthwhile.

In "Florida License Trial Opens in Lawsuit by Veiled Woman" (news article, May 28), Saltaana Freeman's lawyer is quoted as saying, "This is about religious liberty," and "Allowing the state to chip away at religious liberties is not a path we want to go down".

Fries and Krishnan argue that in the context of licensing trials of new drugs these debates are irrelevant and misleading.

It is therefore now accepted by the FDA as a standard comparator regimen for licensing trials in advanced colorectal cancer.

In summary, data from the 2 licensing trials comparing fidaxomicin versus vancomycin suggest that this drug has the potential to substantially improve outcomes from this important healthcare-associated infection.

33 In relation to effectiveness, we need greater attention to postmarketing research in day to day hospital and primary care settings to confirm that subsequent experience replicates the results of licensing trials.

Also a common comparator was missing in the German submission as well as an appropriate comparator which was not used as licensed (within trials).

British entrepreneur Tanya Clarke runs Invegrow, the first company to campaign for the introduction of hemp in Malawi, procuring the first license to trial the crop in October 2015.

The CommissiOn will have the power to revoke licenses and recommend trials in the state courts for offenses, such as bribery.

Hagel and several partners raised money from hundreds of investors, telling them that they were buying the chance to compete for the licenses through comparative trials, which would be adjudicated by the F.C.C.

And though cost has been cited as one of the major restrictive factors preventing drug companies from rolling out Ebola treatments across Africa, the WHO said it "would not recommend any drug that has not gone through the normal process of licensing and clinical trials".